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1. Introduction
1.1. Clinical and genetic aspects
Down syndrome (DS) or trisomy 21 is the most common genetic disorder with a prevalence
of 1 in 660 live births [1]. In 1959, Lejeune and colleagues discovered the genetic basis of DS
and named as trisomy of chromosome 21, which is the smallest human autosomal chromo‐
some [2]. Trisomy 21 can occur as three types of chromosomal abnormalities: free trisomy
21, translocation or mosaicism. Free trisomy 21 is characterized by the presence of three
complete copies of chromosome 21, occurring in about 90-95% of DS cases [3-5]. More than
90% of the cases of chromosomal nondisjunction are of maternal origin, mainly during
meiosis I, about 5% involve an additional paternal extra chromosome and a small propor‐
tion (2%) is consequence of post-zygotic mitotic non-disjunction [6]. Translocations are at‐
tributed to 1-7% of the cases, with Robertsonian translocation involving chromosomes 14
and 21 being the most common type. Mosaicism, characterized by some cells containing 46
chromosomes and others with 47 chromosomes (with an extra chromosome 1), is reported in
1-7% of DS cases [3-5].
DS phenotype is complex and varies among individuals, who may present a combination of
dysmorphic features and developmental delay [7]. The intellectual disability is a characteristic
observed in all cases and the most frequent clinical features include muscular hypotonia (99%),
diastasis of the muscle rectus of abdomen (90%), upslanted palpebral fissures (90%), microce‐
phaly (85%), flat occipital (80%), joint hyperextension (80%), broad hands with short fingers
(70%), short stature (60%), clinodactyly of fifth finger (50%), epicanthal fold (40%), low-set ears
(50%), single palmar crease (40%), atlantoaxial instability (15%) and label-femoral instability
(10%) [8]. On average, 50-70% of children with DS have congenital heart defects, such as ventric‐
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ular septal defect, atrial septal defect, tetralogy of Fallot, patent ductus arteriosus and atrioven‐
tricular  septal  defect  [3,4,9].  There  are  also  ocular  problems,  such  as  refractive  errors,
nystagmus, abnormalities of the retina, among others [10]. About 80% of cases present hearing
loss, which can be conductive, sensorineural, or mixed [11]. Thyroid dysfunction, particularly
hypothyroidism [9], periodontal diseases [10], upper airway obstruction [12] and hypogonad‐
ism [14] are more frequent in individuals with DS than in the general population. Other impor‐
tant clinical aspects of DS include immunodeficiency [15], increased risk for hematological
disorders and leukemia [16] and early onset of Alzheimer's disease [17].
The development of secondary sexual characteristics in DS is similar to other adolescents.
The fetal oogenesis of women with the syndrome appears to be normal and, therefore, they
are capable of reproduction [18]. On the other hand, men have diminished reproductive ca‐
pacity, showing testicular histology compatible with oligospermia and, frequently, hypogo‐
nadism [19]. However, there have been reports of men with Down syndrome who have
fathered pregnancies [20].
2. Genetic counseling
Genetic counseling can be defined as a communication process that takes care of the human
problems associated with the occurrence or recurrence of a genetic disease in a family with
the purpose of providing individuals and families comprehensive understanding of all the
implications related to genetic disease under discussion, the options that the current medi‐
cine offers for therapy or for reducing the risk of occurrence or recurrence of the disease and
psychotherapeutic support [21,22].
For DS, a well-established risk factor is advanced maternal age at conception [23,24]. The es‐
timated risk for fetal trisomy 21 for a woman aged 20 years at 12 weeks of gestation is about
1 in 1000, and the risk of such woman delivering an affected baby at term is 1 in 1500. The
risk for this aneuploidy for a woman aged 35 years at 12 weeks of gestation is about 1 in 250
and the risk of delivering an affected baby at term is 1 in 350 [25].
Although there is considerable variation in the physical features of individuals with DS, most
individuals present with a range of characteristics that enable clinical diagnosis of the syn‐
drome [3,4,7]. However, cytogenetic investigation of individuals who present with clinical
characteristics of DS is fundamental to establish a precise diagnosis, which may have implica‐
tions in the genetic counseling process, once it is very important in determining the recurrence
risk of the syndrome. In addition, the karyotype analysis of affected individuals identifies cases
that may have been inherited making necessary the investigation of the parents' karyotypes. In
this case, the cytogenetic investigation of the genitors is essential to establish the risk of recur‐
rence of the syndrome in future generations. Thus, all individuals with a diagnosis suggestive
of DS should be referred to a genetic counseling service.
Accurate estimation of recurrence risks depends upon the verification of the individual’s
karyotype. Cases of free trisomy 21 and mosaicism generally do not recur in siblings of indi‐
viduals with DS. For women with maternal age <35 at previous trisomy 21, the revised risk
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is the age-related risk times 3.5. For those with maternal age ≥35 at previous trisomy 21, the
revised risk is the age-related risk times 1.7 [26]. So, these risk times implies that other fac‐
tors might influence the risk for DS in young mothers [27]. On the other hand, translocation
may be recurrent. If neither parent carries a balanced translocation, the DS recurrence risk is
low, probably similar to that of free trisomy 21. However, if one of the parents is the carrier
of a balanced translocation, the risk of recurrence is dependent on the type of translocation
and the sex of the carrier parent. In the case of Robertsonian translocations involving chro‐
mosome 13, 14, 15 or 22 and the chromosome 21, the recurrence risk at time of amniocentesis
is of up to 17% when the mother is the carrier and of up to 1.4% when the carrier of this
balanced translocation is the father. On the other hand, if one of the parents is the carrier of
a balanced translocation involving two chromosomes 21, the recurrence risk of DS is 100%
[26]. Thus, once diagnosed as a case of DS due to a translocation, a karyotype analysis of
both parents is recommended.
For an individual with DS, the theoretical chance to have a child with DS is 50%, and 66%
when both partners have DS. However, empiric risks are difficult to estimate, once the re‐
production rates are low. Empiric data indicate a 30–50% chance of a woman with DS have a
child with DS [26]. However, considering that the rate of fetal death between 11 weeks and
term is about 43% for trisomy 21 [28], the chance of birth of a child with DS decreases. For
individuals with mosaicism, the maximum theoretical recurrence risk is as high as 50%, but
is dependent upon the proportion of trisomic gonadal cells and whether the other partner
has DS as well [26].
Genetic counseling is also important to guide the parents about caring for the child with DS. Be‐
cause individuals with DS often experience delays in reaching various developmental mile‐
stones, early intervention with speech therapy, occupational therapy, and physical therapy is
recommended as it maximizes long-term outcomes [29]. As healthcare has improved for indi‐
viduals with DS, the average life expectancy has increased by more than 30 years, from an aver‐
age of 25 years of age in 1983 to almost 60 years of age in 2000 [30]. A study performed between
1985–2004 in England showed that the one-year survival of live births with DS increased, espe‐
cially in babies with cardiovascular malformations, reaching almost 100% [31], and a more re‐
cent study showed that the 25-year survival of DS individuals is about 87.5% [32].
Genetic counselors should balance the negative aspects of DS, such as birth defects, medical
complications, and developmental delay, with positive aspects like available treatments, thera‐
pies, and the ability for people with DS and their families to enjoy a high quality of life [33].
3. Prenatal screening and diagnosis
There are several methods that allow the early detection of DS in prenatal phase. At this
point, it is not possible avoid congenital malformations or genetic diseases, but the objective
is its early detection, looking for emotional and psychological preparation for parents and
family and adequate medical support and monitoring for the child’s birth. Furthermore, ear‐
ly detection allows treatment of malformations of the complications that may occur, pre‐
venting or attenuating their evolution through surgical correction in utero.
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There are some methods used to screen fetus with DS that allow the prenatal diagnosis of
the syndrome. Among the screening methods are the nuchal translucency test, the measure‐
ment of maternal serum concentrations of various fetoplacental products and fetal ultra‐
sound. The nuchal translucency (NT) test is the measurement of the fluid filled fold at the
back of the fetal neck in the first trimester of pregnancy, performed through transabdominal
or transvaginal sonography. The test is performed between the 11th and 13th weeks of ges‐
tation and the minimum fetal crown–rump length (CRL) should be 45 mm and the maxi‐
mum 84 mm. Fetal NT increases with CRL and therefore it is essential to take gestation into
account when determining whether a given NT thickness is increased [25]. The excess skin
in the fetus may be the consequence of excessive accumulation of subcutaneous fluid behind
the fetal neck which could be visualized by ultrasonography as increased NT in the third
month of intrauterine life [34]. Nowadays, it is well established that the measurement of fe‐
tal NT thickness provides effective and early screening for trisomy 21 and other major aneu‐
ploidies, such as Edwards syndrome (trisomy 18) and Patau syndrome (trisomy 13) [34-36]
besides for screening of congenital heart disease [37]. In case of abnormality in NT measure‐
ment, additional tests are needed to elucidate the cause of increased nuchal fold.
Pregnancies with fetal aneuploidies are associated with altered maternal serum concentrations
of various fetoplacental products, including alpha-fetoprotein (AFP), free chorionic gonadotro‐
pin (β-hCG), unconjugated estriol (uE3), inhibin A (INH-A) and pregnancy associated plasma
protein-A (PAPP-A) [38-42]. The measurement of concentrations of maternal serum AFP, β-
hCG and uE3, the triple test, is one of a range of screening tests that are used to identify pregnant
women whose fetus is likely to be affected by trisomy 21 and who should then be offered a diag‐
nostic test. AFP is produced in the yolk sac and fetal liver, while uE3 and hCG are produced by
the placenta. Elevated β-hCG concentration and low levels of AFP and uE3 suggests the pres‐
ence of a fetus with DS [38-40]. The test is performed in second trimester of pregnancy and the
values should be adjusted to gestational age. The expected detection rate and false-positive rate
are about 73 - 78% and 7.5 - 9%, respectively [43].
The incorporation of INH-A into maternal serum DS screening in the second trimester,
along with AFP, hCG and uE3, is named quadruple test. INH-A is a glycoprotein mainly se‐
creted from the corpus luteum and the placenta [44] and its concentration is raised in the
serum of pregnant women carrying a fetus with DS [42]. The quadruple test presents expect‐
ed detection rate and false-positive rate about 79 - 82% and 6.5 - 7.8%, respectively [43]. The
measurement of PAPP-A is also used as a screening gestations of fetus with DS in the first
trimester, once the maternal serum concentration of this protein are reduced in these women
[41]. The measurement of PAPP-A at 10–14 weeks of pregnancy is used to screen for fetal DS
during the first trimester of pregnancy [45,47].
The fetal ultrasound is also considered a method of screening for DS, once any change in the
development of organs or structures is easily visualized. The objective is the detection of
major and soft markers of aneuploidy, including alterations in central nervous system, face,
neck, heart, gastrointestinal tract, genitourinary tract among others [47]. Besides increased
nuchal translucency in the first trimester, alterations commonly detected in DS in the second
trimester of gestation include lack of visualization of the nasal bone [48], reduced femur and
humerus, mild pyelectasis, hyperechoic bowel and echogenic intracardiac focus [47,49].
Down Syndrome6
Importantly, any suspect result of the markers mentioned implies the genetic analysis of the
fetus, the only way to accurate diagnosis. The methods for obtaining fetal cells for analysis
vary with gestational age. Among the invasive methods for obtaining fetal cells, chorionic
villus sampling (CVS) allows diagnosis in the first trimester of pregnancy (between the 10th
and 13th weeks of gestation) [50]. The procedure involves aspiration of trophoblastic tissue
under continuous ultrasound monitoring, performed via trans-cervical or trans-abdominal.
Studies have showed that the risk miscarriage associated to this procedure is about 0.6-1.1%
[51,52] and the procedure is not recommended for pregnant women that present bleeding
due to an increase in the procedure-related fetal loss rate [51].
The amniocentesis is the method indicated for obtaining fetal cells after 15 weeks of gesta‐
tion [53]. This requires taking a small sample of amniotic fluid transabdominally under ul‐
trasound guidance. The procedure-related fetal loss rate is about 0.4-0.8 % [51,52]. After 20th
week of gestation, the option is percutaneous umbilical blood sampling or cordocentesis,
which involves direct sampling of fetal blood from the umbilical cord. The procedure-relat‐
ed loss rate is about 1.0-1.5% and cordocentesis with placenta penetration had a significantly
higher rate of fetal loss [54-56].
Considering the risks which accompany invasive methods for obtaining fetal cells [51,52,56],
the use of noninvasive methods could be a good option. Several methods to develop a non‐
invasive prenatal test for trisomy 21 and other aneuploidies have been investigated, includ‐
ing the use of cell-free fetal nucleic acids [57-60] and nucleated red blood fetal cells present
in maternal peripheral blood [61,62]. Although studies have showed that noninvasive meth‐
ods for obtaining fetal cells allow noninvasive prenatal diagnosis for a variety of genetic
conditions and may in future form part of national antenatal screening programs for DS and
other common genetic disorders, a major obstacle in the widespread application of noninva‐
sive methods for obtaining fetal cells in clinical diagnostics is still that fetal cells / DNA con‐
stitutes a small percentage of total cell / DNA in maternal blood and the inconsistencies in
enrichment strategies of these fetal samples [62,63].
After obtaining fetal cells, conventional karyotype analysis has been used for the past few
decades as the gold standard for the prenatal diagnosis of numerical and major structural
chromosomal abnormalities. Nevertheless, it is labor intensive and requires skilled chromo‐
somal analysis with an average reporting time of 14 days. However, the availability of mo‐
lecular techniques such as fluorescence in situ hybridization (FISH) has allowed the prenatal
diagnosis of most frequent trisomies (21, 13, 18) and aneuploidy of sex chromosomes quick‐
ly and accurately, obtaining result from one to two days [64,65]. In addition, the technique
of polymerase chain reaction quantitative fluorescent (QF-PCR), besides other molecular
techniques such as the multiplex ligation-dependent probe amplification (MLPA) test and
DNA sequencing, can also be used for a rapid diagnosis of aneuploidies [66-68]. It has been
showed that QF-PCR technique presents 95.4% sensitivity, 100% specificity, 99.5% efficiency
and is less laborious than the FISH technique, less time consuming, and some results were
obtained in eight hours. The sensitivity, specificity, and efficiency of the assay for detecting
DS using this technique are about 95.4%, 100%, and 99.5%, respectively [69]. Molecular tech‐
niques also enable the diagnosis of pre-implantation embryos in assisted reproduction [70].
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It is important to note that the examinations of prenatal diagnosis should not be offered
without the guidance of a geneticist to explain the risks to the parents and especially the im‐
plications of possible results. Early diagnosis helps couples to program for the treatment of
the consequences of the syndrome diagnosed, preventing further damage and making possi‐
ble the early stimulation of the patients, aiming their better integration into society.
4. Gene expression and DS phenotype
In a recent review of chromosome 21 content, 552 genes were identified in the long arm of
the chromosome (21q) [71], including 161 protein-coding genes cataloged in the Reference
Sequence database of the National Center for Biotechnology Information (NCBI). The re‐
maining 391 gene models are referred to as novel genes or non-cataloged genes, which
could be protein-coding genes or functional RNA genes. Considering that the genetic basis
of DS is the presence of three copies of chromosome 21, the first and most commonly accept‐
ed hypothesis for DS phenotype is that the genes in triplicate are overexpressed and, thus,
the dosage imbalance of genes on chromosome 21 is responsible for the molecular dysfunc‐
tions in DS [72]. Among the genes present in chromosome 21, may be highlighted some de‐
scribed in the literature with overexpression associated with phenotypes of DS, most
influencing the structure or function of the central nervous system (Table 1). Location of
these genes on chromosome 21 is presented in Figure 1.
Gene symbol* Gene location* Candidate gene for Reference
APP 21q21.3 Neurodegeneration [73,74]
BACH1 21q22.11 Alzheimer's disease-like neuropathological changes [75]
DOPEY2 21q22.2 Functional brain alterations and mental retardation [76]
DSCAM 21q22.2 Mental retardation and the precocious dementia [77]
DYRK1A 21q22.13 Leukemogenesis [78]
Impaired brain development [79]
Early onset of neurofibrillary degeneration [80]
ERG 21q22.3 Alzheimer's disease-like neuropathological changes [75]
OLIG2 21q22.11 Developmental brain defects [81]
SIM2 21q22.13 Impairment of learning and memory [82]
Pathogenesis of mental retardation [83]
SOD1 21q22.11 Neurodegeneration [84]
PCP4 21q22.2 Abnormal neuronal development [85]
* http://www.ncbi.nlm.nih.gov/gene
Table 1. Chromosome 21 gene-located with overexpression in DS influencing the structure or function of the central
nervous system.
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Figure 1. Location of genes overexpressed in DS influencing the structure or function of the central nervous system.
Figure adapted from the NCBI Map Viewer database (http://www.ncbi.nlm.nih.gov/mapview/).
However, although elevated levels of gene expression on chromosome 21 in trisomy 21 tissues
have been reported in several studies, there are evidences that increased copy number does not
always correspond with increased gene expression level or even less with increased gene func‐
tion [86,87]. In addition, studies have showed up- or downregulation of genes located on diso‐
mic chromosomes, indicating that the phenotype is due to an unstable environment resulting
from the dosage imbalance of the hundreds of genes on chromosome 21 which determines a
non-specific disturbance of genomic regulation and expression [88-90].
Besides altered pattern of gene expression, regulatory mechanisms are also altered in triso‐
my 21. Individuals with DS present altered pattern of DNA methylation in genes present in
two or three copies with functional consequences in gene expression [91,92]. More recent
studies have shown that trisomy 21 results in altered expression of microRNAs, small mole‐
cules of noncoding RNA involved in post-transcriptional gene regulation, which could re‐
sult in abnormal expression of specific proteins and contribute to the DS phenotype [93-97]
The complete sequencing of chromosome 21 provided basis for the identification of candi‐
date genes for DS phenotype manifestations. Currently, there are several genes located on
chromosome 21 associated to DS phenotype and the involvement of other genes still will be
elucidated with advances of genomics and proteomics. The knowing of these gene functions
and their contribution for DS phenotype are fundamental for the understanding of the syn‐
drome and for providing basis for the planning of therapeutic strategies that could contrib‐
ute to improve the quality of life of DS individuals.




Although individuals with trisomy 21 present several characteristics that make possible the
clinical diagnosis of DS, the confirmation of the diagnosis by cytogenetic analysis is essential
to establish the recurrence risks of the syndrome. We highlight the importance of the prena‐
tal diagnosis of DS to provide the needed healthcare for the child, to prepare the family
emotional and psychologically and to plan early intervention therapies. The successful con‐
trol of pharmacological and clinical problems of patients with DS is the biggest medical
challenge and depends on the understanding of unbalanced metabolism induced by high
expression of the genes located on chromosome 21.
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